New hope for hard-to-treat lymphoma: drug combo targets cancer from two angles
NCT ID NCT06054776
First seen Jan 10, 2026 · Last updated May 23, 2026 · Updated 22 times
Summary
This study tests whether a combination of three drugs—acalabrutinib, obinutuzumab, and glofitamab—is safe and effective for people with mantle cell lymphoma that has come back or stopped responding to prior treatments. About 40 adults will receive the drugs, which work by blocking cancer growth signals and helping the immune system attack cancer cells. The main goals are to check side effects and see how many patients achieve a complete response (no cancer detected).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.